United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

Hi, The UK has approved Pfizer and BioNTech's coronavirus vaccine, becoming the first Western country to give a vaccine an OK. The plan is to make the vaccine available next week. 

UK approves its first vaccine

Care home residents and people over the age of 80 will be among the first to receive the Pfizer-BioNTech COVID-19 vaccine, when the U.K. rollout starts next week.

Who will be first in line for the Pfizer-BioNTech COVID-19 vaccine?

Senior citizens will be first in line as the UK is the first country to approve Pfizer's vaccine.

Pfizer Covid-19 vaccine approved for use in UK

The U.K.'s regulator had been delegated much of the work to authorize Europe's medicines, and seemed better prepared than most to approve the vaccine.

How the U.K. became first to approve the Pfizer-BioNTech vaccine, and are there dangers authorizing so fast?

The UK has approved Pfizer and its German partner BioNTech's COVID-19 vaccine — but regulators in the US are yet to make a decision on authorization. The UK's vaccine regulator approved the shot Wednesday morning, making it the first western country to authorize a COVID-19 vaccine. Vaccinations will start next week, the government said.

The UK has approved Pfizer and BioNTech's COVID-19 vaccine, but the US is still waiting. Here's why.

The U.K. has become the first country to approve the Pfizer-BioNTech Covid-19 vaccine, with preparations under way to begin the rollout next week.

U.K. Becomes First Country to Approve Pfizer's Covid-19 Vaccine

AstraZeneca

CureVac B.V

Johnson & Johnson

Moderna

Novavax

Here's what you need to know about all of the leaders in the coronavirus vaccine race.

COVID Vaccine Stocks Update: Where Things Stand Now

The vaccine will be available across the U.K. starting next week with the elderly and frontline healthcare workers being the first to receive a shot.

U.K. Approves Pfizer-BioNTech's Covid-19 Vaccine, The First Country To Do So

U.K. becomes first country to approve a coronavirus vaccine, with immunisations to start within days for those most at risk

Pfizer and BioNTech's COVID-19 vaccine wins U.K. approval — rollout to begin next week

This is an historic moment. The beginning of the end of the pandemic.

Vaccine approval is a historic moment for the UK

The UK's medicines regulator has approved the BioNTech/Pfizer vaccine against COVID-19 for emergency use, the companies said today. The UK is the first country to approve the vaccine for widespread use — paving the way for some of the most “high risk” citizens, such as elderly care home residents, to get the jab before the end […]

The UK approves the BioNTech/Pfizer COVID-19 vaccine for emergency use

Pfizer Inc (NYSE: PFE) and its German partner BioNTech SE (NASDAQ: BNTX) said Wednesday they have received regulatory approval in the United Kingdom for their COVID-19 vaccine. What Happened: The go-ahead from the Medicines and Healthcare Products Regulatory Agency (MHRA) means the U.K. has become the first country to approve a COVID-19 vaccine on an emergency basis ahead of the United States and the European Union.

Pfizer-BioNTech COVID-19 Vaccine Gets UK Approval For Emergency Use

The UK has become the first Western country to officially have a new coronavirus vaccine, marking a potential exit route out of the pandemic. And it's happened in record time.   The vaccine developed by US drugmaker Pfizer and the small German biotech, BioNTech, can be used in the UK, after the independent regulatory body in the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) signed off the vaccine.

Regulator says yes to Pfizer and BioNTech: UK becomes first Western country to have a coronavirus vaccine

The U.K. has authorized the Pfizer/BioNtech coronavirus vaccine, making it the first country in the world to do so.

UK becomes first country to approve the Pfizer-BioNTech coronavirus vaccine for use

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the Medicines & Healthcare Products Regulatory Agency (MHRA) in the U.K. has granted a temporary authorization for emergency use for their COVID-19 mRNA vaccine (BNT162b2), against COVID-19. This constitutes the first Emergency Use Authorization following a worldwide Phase 3 trial of a vaccine to help fight the pandemic. Pfizer and BioNTech are anticipating further regulat

Pfizer and BioNTech Achieve First Authorization in the World for a Vaccine to Combat COVID-19

The UK's independent healthcare regulator has approved use of the Pfizer/BioNtech COVID-19 vaccine.

UK approves use of Pfizer's coronavirus vaccine

LM Ericsson Telefon

Twenty-First Century Fox

General Electric

Lyft

Sturm, Ruger & Company

Alibaba

Growth stocks to buy shouldn't mean pricey or risky. Here are 7 safe growth stocks that look set for a great 2021.

7 Safe Growth Stocks To Buy For 2021 Catalysts

The European Medicines Agency said Tuesday it has received conditional marketing approval applications from Pfizer Inc. (NYSE: PFE)-BioNTech SE – ADR (NASDAQ: BNTX) and Moderna Inc (NASDAQ: MRNA), the two frontrunners in the development of a coronavirus vaccine.  The decision isn't likely to come early, thereby pushing out the vaccine launch timeline.

European Drug Regulator Gives 6-Week Time Frame For Opinions On Pfizer-BioNTech, Moderna COVID-19 Vaccines

United Continental Hlds

The COVID-19 vaccine has taken flight en route to the US.  Pfizer has tasked United Airlines with transporting the first doses of its vaccine to the US, the Wall Street Journal reported on Friday, in preparation for an expected emergency authorization from the Food and Drug Administration scheduled to come in the upcoming weeks.

How United Airlines overcame one of the largest limitations to being transporting Pfizer's COVID-19 vaccine to the US

General Motors

Kroger

Snowflake

Costco

Barrick Gold

Wells Fargo

In the third quarter, Berkshire Hathaway made a number of changes. Here are seven Warren Buffett stocks that ought to be on your radar.

7 Warren Buffett Stocks That Belong On Your 2021 Watchlist

AbbVie

Bristol-Myers

Merck

Berkshire's latest filing revealed the Oracle of Omaha and his team opening new positions in four pharma giants as of late. From a quality standpoint, all companies seem like a natural fit considering Buffett's reported preference for wide-moat businesses.

Buffett Buys Pharma: Two Out Of Four Seem Compelling

Moderna and Pfizer applied to the EU's vaccine regulator this week.

Europe May Not Get Covid-19 Vaccine Before 2021, Earliest Approval Process Scheduled For December 29

Gilead Sciences

Should you buy these drugmaker stocks for their juicy dividend yields?

3 Pharma Stocks With Dividends Above 4% to Buy Now

Eli Lilly

Shares of Moderna, Inc. (MRNA), Pfizer, Inc. (PFE) and AstraZeneca plc (AZN) are poised for substantial gains on encouraging final-stage trial results.

COVID-19 Vaccine Race Heats Up: Drugmarkers on Final Lap

Allogene Therapeutics Inc

Atara Biotherapeutics

Cellectis SA

CRISPR Therapeutics

Novartis

Allogeneic cell therapies have a significant cost, convenience and efficiency advantage over autologous. Data from three of the leaders: Allogene, Atara and CRISPR are expected in the next 12-to-24 months to further elucidate safety and efficacy.

News for Pfizer Stock (PFE)